Install
Your go-to source for the latest news in health, science and medicine. Sign up for STAT+ for exclusive analysis of biotech, pharma, and the life sciences.
- 209articles · 30d
- 1+ day agolatest article
- Aug 14, 2026earliest in window
- 94%with images
- 249avg words
- Medical 152
- Health & Wellness 141
- Health 103
- Science & Technology 48
- Business & Industrial 38
- Economy, Business & Finance 22
- Politics 20
- Politics2 18
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Why two promising heart drugs flopped and what's next
2+ day, 20+ hour ago (222+ words) By Adam Feuerstein, Elaine Chen, and Allison DeAngelis On this week’s episode of “The Readout LOUD”: The pharma industry invested billions of dollars to develop drugs heralded as the next era in the treatment of heart disease — but why did…...
The gifts from pharma companies that keep on giving
2+ day, 21+ hour ago (218+ words) Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for more than three decades. His stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is…...
Pharmalittle: We're reading about another Novartis trial failure, a Novo Nordisk setback, and more
5+ day, 53+ min ago (369+ words) Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for more than three decades. His stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is…...
Novartis gets multiple sclerosis win with BTK inhibitor
1+ week, 5+ day ago (270+ words) By Elaine Chen and Helen Branswell Good morning. I know this week probably feels extra long as we approach Labor Day weekend, but we will get through it together. President Trump yesterday announced that his administration has made deals with…...
Pharmalittle: We're reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more
1+ week, 5+ day ago (258+ words) STAT Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more President Trump has announced the next round of pricing deals with drugmakers Andrew covers the biopharma industry, scientific research, and public health across…...
In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
2+ week, 2+ day ago (138+ words) AstraZeneca on Friday detailed the surprise failure of a closely watched heart disease clinical trial, laying out how its experimental drug offered no additional benefits for patients who were largely already on another type of medicine — the latest twist in…...
Pharmalittle: We're reading about a GSK shingles shot, U.S. employers dropping GLP-1 coverage, and more
2+ week, 4+ day ago (352+ words) Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for more than three decades. His stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is…...
Pharmalittle: We're reading about RFK Jr. vaccine disclosures, a Merck loss over Medicare prices, and more
2+ week, 5+ day ago (381+ words) Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for more than three decades. His stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is…...
Pharmalittle: We're reading about a big Roche investment in the U.S., estrogen patch shortages, and more
3+ week, 2+ day ago (299+ words) STAT Pharmalittle: We’re reading about a big Roche investment in the U.S., estrogen patch shortages, and more FDA nominee Heidi Overton’s loyalty to President Trump could hurt her confirmation chances Pharmalot Columnist, Senior Writer Ed’s stories explore prescription drug pricing,…...
Pharmalittle: We're reading about a setback for Eyepoint, a win for Amylyx, and more
3+ week, 5+ day ago (252+ words) STAT is a media company focused on finding and telling compelling stories about health, medicine, and scientific discovery. We produce daily news, investigative articles, and narrative projects in addition to multimedia features, podcasts, and opinion pieces. We tell our stories…...